Kerry Rout George, Mahapatra Soumya Ranjan, Nayak Sanghamitra, Naik Hemangini, Kisku Kanika, Panigrahi Bijayananda, Misra Namrata, Majhi Sanatan
Department of Biotechnology, Utkal University, Vani Vihar, Bhubaneswar, Odisha 751004 India.
Centre for Biotechnology, Siksha 'O' Anusandhan (Deemed to be University), Kalinga Nagar, Bhubaneswar, Odisha 751003 India.
In Silico Pharmacol. 2025 Apr 24;13(2):68. doi: 10.1007/s40203-025-00353-1. eCollection 2025.
Diabetes is one of the oldest diseases known to occur in humans and is regulated by a complex interplay of metabolic, genetic, and environmental factors. Several therapeutic options exist, including medications, exercise, improved health measures, psychological and mental well-being, and amelioration of disparity and depression. Current therapeutic options although are effective, they tends to display side effects that includes significant complications like gastrointestinal discomfort, decreased effectiveness and weight gain. Plant-derived bioactive substances with antidiabetic and/or hypoglycaemic properties have been found to be effective, however, the mechanism of action of the majority of herbs are still being characterized and standardized. However, in the present in-silico prediction for phytocompounds, Rutin (RU) and Morin (MO) revealed them to be more effective than or equal to conventional inhibitors in blocking the enzymes and receptors that contribute to diabetes development. Results of the in-silico investigations have clearly demonstrated the importance of RU and MO in binding diabetic-susceptible enzymes (alpha-amylase, DPP-4, and maltase-glucoamylase) and receptors (GLP-1R, SGLT1 and SGLT2). Additionally, in vitro antidiabetic enzymatic assays demonstrated the possible inhibitory activity of RU and MO against two diabetes-related molecular targets.
糖尿病是已知发生在人类身上最古老的疾病之一，它受代谢、遗传和环境因素的复杂相互作用调节。目前有多种治疗选择，包括药物治疗、运动、改善健康措施、心理和精神健康，以及缓解差异和抑郁。当前的治疗选择虽然有效，但往往会出现副作用，包括胃肠道不适、疗效降低和体重增加等严重并发症。已发现具有抗糖尿病和/或降血糖特性的植物源生物活性物质是有效的，然而，大多数草药的作用机制仍在研究和标准化。然而，在目前对植物化合物芦丁（RU）和桑色素（MO）的计算机模拟预测中，发现它们在阻断导致糖尿病发展的酶和受体方面比传统抑制剂更有效或与之相当。计算机模拟研究结果清楚地证明了RU和MO在结合糖尿病易感酶（α-淀粉酶、二肽基肽酶-4和麦芽糖酶-葡糖淀粉酶）和受体（胰高血糖素样肽-1受体、钠-葡萄糖协同转运蛋白1和钠-葡萄糖协同转运蛋白2）方面的重要性。此外，体外抗糖尿病酶活性测定证明了RU和MO对两个糖尿病相关分子靶点可能具有抑制活性。
